Cargando…
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients()
BACKGROUND/AIMS: Interferon and ribavirin combination therapy for chronic hepatitis C induces a low response rate in human immunodeficiency virus (HIV) infected patients. To assess the impact of intensification of interferon administration and of the addition of amantadine on the efficacy and safety...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Association for the Study of the Liver. Published by Elsevier Ireland Ltd.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126192/ https://www.ncbi.nlm.nih.gov/pubmed/15288482 http://dx.doi.org/10.1016/j.jhep.2004.04.016 |
_version_ | 1783516095733301248 |
---|---|
author | Puoti, Massimo Zanini, Barbara Quinzan, Gian Paolo Ravasio, Laura Paraninfo, Giuseppe Santantonio, Teresa Rollo, Adriano Artioli, Stefania Maggiolo, Franco Zaltron, Serena MASTER HIV/HCV Co-infection study group Raise, Enzo Mignani, Ermenegildo Resta, Francesco Verucchi, Gabriella Pastore, Giuseppe Suter, Fredy Carosi, Giampiero |
author_facet | Puoti, Massimo Zanini, Barbara Quinzan, Gian Paolo Ravasio, Laura Paraninfo, Giuseppe Santantonio, Teresa Rollo, Adriano Artioli, Stefania Maggiolo, Franco Zaltron, Serena MASTER HIV/HCV Co-infection study group Raise, Enzo Mignani, Ermenegildo Resta, Francesco Verucchi, Gabriella Pastore, Giuseppe Suter, Fredy Carosi, Giampiero |
author_sort | Puoti, Massimo |
collection | PubMed |
description | BACKGROUND/AIMS: Interferon and ribavirin combination therapy for chronic hepatitis C induces a low response rate in human immunodeficiency virus (HIV) infected patients. To assess the impact of intensification of interferon administration and of the addition of amantadine on the efficacy and safety of standard anti-hepatitis C virus (HCV) treatment in HIV-infected patients. METHODS: Multicentre, prospective, open-label, randomized, phase III clinical trial. Eighty co-infected patients were randomized to receive ribavirin 800–1000 mg/day in combination with, group A: interferon alpha2a 3 MIU thrice weekly; group B: IFNα2a 3 MIU daily, plus amantadine 200 mg/day; treatment duration was 24–48 weeks according to HCV genotype. RESULTS: Forty-one patients were randomized in group A and 39 in group B. Intention-to-treat analysis showed a sustained virological response, defined as HCV-RNA negativization, 6 months after stopping treatment in 22% of patients from group A and 13% from group B (P>0.05). The lack of a 2-log drop in HCV-RNA levels after 12 weeks of treatment showed a 100% predictive value of lack of sustained response. CONCLUSIONS: Amantadine addition and interferon intensification do not improve the low efficacy of combination of interferon alfa plus ribavirin in HIV/HCV co-infected patients. Patients with no early virologic response did not have any probability of sustained response. |
format | Online Article Text |
id | pubmed-7126192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | European Association for the Study of the Liver. Published by Elsevier Ireland Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71261922020-04-08 A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients() Puoti, Massimo Zanini, Barbara Quinzan, Gian Paolo Ravasio, Laura Paraninfo, Giuseppe Santantonio, Teresa Rollo, Adriano Artioli, Stefania Maggiolo, Franco Zaltron, Serena MASTER HIV/HCV Co-infection study group Raise, Enzo Mignani, Ermenegildo Resta, Francesco Verucchi, Gabriella Pastore, Giuseppe Suter, Fredy Carosi, Giampiero J Hepatol Article BACKGROUND/AIMS: Interferon and ribavirin combination therapy for chronic hepatitis C induces a low response rate in human immunodeficiency virus (HIV) infected patients. To assess the impact of intensification of interferon administration and of the addition of amantadine on the efficacy and safety of standard anti-hepatitis C virus (HCV) treatment in HIV-infected patients. METHODS: Multicentre, prospective, open-label, randomized, phase III clinical trial. Eighty co-infected patients were randomized to receive ribavirin 800–1000 mg/day in combination with, group A: interferon alpha2a 3 MIU thrice weekly; group B: IFNα2a 3 MIU daily, plus amantadine 200 mg/day; treatment duration was 24–48 weeks according to HCV genotype. RESULTS: Forty-one patients were randomized in group A and 39 in group B. Intention-to-treat analysis showed a sustained virological response, defined as HCV-RNA negativization, 6 months after stopping treatment in 22% of patients from group A and 13% from group B (P>0.05). The lack of a 2-log drop in HCV-RNA levels after 12 weeks of treatment showed a 100% predictive value of lack of sustained response. CONCLUSIONS: Amantadine addition and interferon intensification do not improve the low efficacy of combination of interferon alfa plus ribavirin in HIV/HCV co-infected patients. Patients with no early virologic response did not have any probability of sustained response. European Association for the Study of the Liver. Published by Elsevier Ireland Ltd. 2004-08 2004-05-06 /pmc/articles/PMC7126192/ /pubmed/15288482 http://dx.doi.org/10.1016/j.jhep.2004.04.016 Text en Copyright © 2004 European Association for the Study of the Liver. Published by Elsevier Ireland Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Puoti, Massimo Zanini, Barbara Quinzan, Gian Paolo Ravasio, Laura Paraninfo, Giuseppe Santantonio, Teresa Rollo, Adriano Artioli, Stefania Maggiolo, Franco Zaltron, Serena MASTER HIV/HCV Co-infection study group Raise, Enzo Mignani, Ermenegildo Resta, Francesco Verucchi, Gabriella Pastore, Giuseppe Suter, Fredy Carosi, Giampiero A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients() |
title | A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients() |
title_full | A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients() |
title_fullStr | A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients() |
title_full_unstemmed | A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients() |
title_short | A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients() |
title_sort | randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis c in hiv-infected patients() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126192/ https://www.ncbi.nlm.nih.gov/pubmed/15288482 http://dx.doi.org/10.1016/j.jhep.2004.04.016 |
work_keys_str_mv | AT puotimassimo arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT zaninibarbara arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT quinzangianpaolo arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT ravasiolaura arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT paraninfogiuseppe arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT santantonioteresa arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT rolloadriano arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT artiolistefania arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT maggiolofranco arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT zaltronserena arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT masterhivhcvcoinfectionstudygroup arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT raiseenzo arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT mignaniermenegildo arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT restafrancesco arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT verucchigabriella arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT pastoregiuseppe arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT suterfredy arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT carosigiampiero arandomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT puotimassimo randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT zaninibarbara randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT quinzangianpaolo randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT ravasiolaura randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT paraninfogiuseppe randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT santantonioteresa randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT rolloadriano randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT artiolistefania randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT maggiolofranco randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT zaltronserena randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT masterhivhcvcoinfectionstudygroup randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT raiseenzo randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT mignaniermenegildo randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT restafrancesco randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT verucchigabriella randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT pastoregiuseppe randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT suterfredy randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients AT carosigiampiero randomizedcontrolledtrialoftripleantiviraltherapyasinitialtreatmentofchronichepatitiscinhivinfectedpatients |